Thoracic Surgery Branch
Information for Patients
Learn more about our clinical trials and the highly specialized care teams who lead them.
The Thoracic Surgery Branch (TSB) conducts laboratory research pertaining to mechanisms of initiation and progression of thoracic malignancies; translates results of laboratory research to clinical protocols examining novel strategies to improve detection, diagnosis, and treatment of these neoplasms; mentors future leaders in thoracic surgical oncology and translational cancer research; and provides comprehensive clinical support for all patients with thoracic surgical issues at the NIH Clinical Center.
|Position||Degree Required||Contact Name||Contact Email|
|Post-doctoral Fellow - Molecular analysis of thoracic malignancy||Ph.D. or equivalent||Jan Pappasfirstname.lastname@example.org|
|Staff Scientist - Bioinformatics, stem cells, epigenetics||Ph.D. or equivalent||Jan Pappasemail@example.com|
Learn more about CCR research advances, new discoveries and more on our news section.
Research Interests of Branch Members
Dr. David Schrump is a thoracic surgeon who is internationally recognized for surgical expertise pertaining to lung and esophageal cancers, malignant pleural mesothelioma, chest wall sarcomas and pulmonary metastases. His research efforts are focused on the elucidation of epigenetic mechanisms of gene regulation in lung and esophageal cancers and malignant pleural mesothelioma, and the development of epigenetic regimens including chromatin remodeling agents and novel tumor vaccines for the treatment of these neoplasms.
Dr. Chuong Dinh Hoang focuses on thoracic surgical oncology, with emphasis on malignant mesothelioma and thymic neoplasms. His clinical expertise includes all major aspects of thoracic surgery including procedures for lung cancer, other primary lung tumors, mesothelioma, thymic malignancies, esophageal cancer, pulmonary metastases, Pancoast tumors, and tracheal cancers. He is developing a research effort aimed at translating deranged microRNA profiles unique to mesothelioma and other thoracic cancers for biomarker discovery and novel therapeutic strategies.
Dr. Haobin Chen is developing novel epigenetic therapies for small cell lung cancer. He is board certified in both internal medicine and medical oncology.
Dr. Shamus Carr's research builds upon the understanding of tumor biology and the interplay of genetic and epigenetic contributions to the development of cancer. His goal is to identify genetic and/or epigenetic characteristics of an individual tumor that accurately predict prognosis and thus better tailor individualized therapy for patients after surgery. Eventually, these findings may translate into non-invasive means of earlier detection and/or screening.
Physicians, Thoracic Oncology:
Physician-Scientist Early Investigator:
Nurse Practitioners and Research Nurses:
- Cheryl Warga, C.R.N.P., Deborsee Jayaram, C.R.N.P., Lydiah Mutumbi, RN
Patient Care Coordinator:
- Jenny Hauprich
Staff Scientists, Visiting Fellows and Biologists:
- Shivani Dixit, Ph.D., Sudheer K. Gara, Ph.D., Nathanael D. Pruett, Ph.D., Vivek Shukla, Ph.D., Anand Singh, Ph.D., Tuana Tolunay, M.D., Ruihong Wang, Ph.D., Sichuan Xi, M.D., Ph.D., Mary Zhang, Ph.D., Stephanie Shiffka, Ph.D., Xinwei Wu, Ph.D.
- Haitao Wang, Ph.D.
- Jan Pappas, Program Specialist
Center for Cancer Research National Cancer Institute
- Building 10, Room 4-3942
- Bethesda, MD 20892-1201